ROCKVILLE, Md.--(BUSINESS WIRE)--Human Genome Sciences, Inc. (Nasdaq: HGSI) today will report on the progress of its U.S. launch of BENLYSTA® (belimumab) and outline future strategic priorities at a meeting of financial analysts and investors in New York. (A webcast of today’s HGS Analyst and Investor Meeting may be accessed at www.hgsi.com, beginning at 1:00 PM Eastern time.)
